Welcome to our dedicated page for CytomX Therapeutics news (Ticker: $CTMX), a resource for investors and traders seeking the latest updates and insights on CytomX Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CytomX Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CytomX Therapeutics's position in the market.
CytomX Therapeutics announced a clinical collaboration with Merck to evaluate CX-801 in combination with KEYTRUDA in patients with advanced metastatic solid tumors. The Phase 1 first-in-human study is expected to start in the first half of 2024. CX-801 is a masked interferon-alpha2b cytokine designed to activate the immune tumor microenvironment while overcoming systemic toxicities.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) will release first quarter 2024 results and share preliminary Phase 1a data for CX-904 on May 8, 2024. The company specializes in masked, conditionally activated biologic therapeutics and will host a conference call for investors to discuss the updates.
